November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Growing Role of Immunotherapy as Treatment for Lung Cancer
March 3rd 2018Marina C. Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses current advancements with immunotherapy as first- and second-line treatments for patients with lung cancer.
Watch
Identifying Patients With Lung Cancer Who Benefit From Immunotherapy
February 24th 2018Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, discusses biomarkers that may help identify patients with lung cancer who can benefit from immunotherapy agents. Since the introduction of these agents, PD-L1 has been used as a potential biomarker for selecting patients that may benefit from treatment. As PD-L1 is not completely reliable, there is interest in developing additional biomarkers.
Watch
Avelumab Does Not Improve OS Over Docetaxel in NSCLC, Phase III Trial Shows
February 23rd 2018The primary endpoint of improving overall survival was not met in the phase III JAVELIN Lung 200 Trial of avelumab in patients with non–small cell lung cancer, according to Merck KGaA and Pfizer, the co-developers of avelumab.
Read More
Jean-Charles Soria to Receive TAT 2018 Honorary Award for Cancer Drug Development
February 20th 2018Jean-Charles Soria, MD, PhD, will be honored with the Targeted Anticancer Therapies 2018 Honorary Award for cancer drug development. Soria has played a large part in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy for the last 15 years.
Read More
Durvalumab Granted FDA Approval for Locally Advanced NSCLC
February 17th 2018Based on results from the phase III PACIFIC trial, durvalumab has been granted approval by the FDA for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.
Read More
Promising Activity Seen from ERK1/2 Inhibitor in MAPK/ERK Mutations and BRAF/MEK Resistance
February 17th 2018Ulixertinib, a novel ERK1/2 inhibitor, demonstrated encouraging antitumor activity in patients with solid tumors harboring mutations in the MAPK/ERK pathway, according to the results of a phase I study published in <em>Cancer Discovery</em>.
Read More
What Would CMS Proposed Coverage Decision for Next-Generation Sequencing Mean for Oncologists?
February 16th 2018The day when oncologists can order a Medicare-covered next-generation sequencing diagnostic test may be near at hand, but once this change goes into effect, will oncologists be limited to certain tests, labs, and cancer settings? The answer is unclear.
Read More
Lorlatinib Granted Priority Review by FDA for ALK+ NSCLC
February 13th 2018A new drug application for lorlatinib for use in patients with <em>ALK</em>-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK tyrosine kinases inhibitors has been granted a priority review by the FDA.
Read More
Gray Sheds Light on Considerations When Treating NSCLC With Immunotherapy
February 5th 2018Jhanelle E. Gray, MD, recently shared the treatment considerations and decisions she makes when treating patients with non–small cell lung cancer, with a special focus on immunotherapy. Gray, associate member, Director of Thoracic Clinical Research, Moffitt Cancer Center, Tampa, Florida, explained her treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Kathy Albain Named First Huizenga Family Endowed Chair at Loyola University Chicago
January 24th 2018Kathy S. Albain, MD, has been named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine. Funded by Heidi Huizenga, one of Albain’s beholden patients, her husband, and her family, the endowed chair recognizes Albain’s notable contributions as a physician, research, teacher and mentor.
Read More
Afatinib Approval for Lung Cancer Expanded by FDA
January 15th 2018The frontline indication for afatinib (Gilotrif) has been expanded by the FDA to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon <em>EGFR</em> alterations in L861Q, G719X, and/or S768I.
Read More
A Look Back at FDA News in the Month of December
January 3rd 2018The FDA closed out the year by approving several new agents last month, including bevacizumab for glioblastoma, cabozantinib for renal cell carcinoma, nivolumab for melanoma, bosutinib for chronic myeloid leukemia, and pertuzumab for HER2+ breast cancer. In addition, several agents were granted a priority review designation. Here is a look back at all the FDA activity that took place in December.
Read More
Regardless of smoking history, patients with cancer of the lung harboring specific genetic alterations who were treated with targeted therapies experienced longer survival than those patients who did not receive targeted treatment, according to results of a multi-institutional extension study to identify and treat oncogenic driver events.
Read More
Frontline Osimertinib Granted FDA's Priority Review for NSCLC
December 19th 2017A supplemental new drug application (sNDA) for osimertinib (Tagrisso) has been granted a priority review by the FDA as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor <em>EGFR</em> mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).
Read More
Entrectinib Demonstrates Durable Benefit for ROS1-Positive NSCLC
November 28th 2017According to findings presented at the 2017 World Conference on Lung Cancer, the potent and selective inhibitor of ROS1 and TRKentrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with <em>ROS1</em> fusion-positive advanced non–small cell lung cancer.
Read More
Frontline Osimertinib Submitted for Japanese Approval in NSCLC
November 28th 2017AstraZeneca has submitted a supplemental new drug application to Japan's Pharmaceuticals and Medical Devices Agency for the use of the third-generation, irreversible EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) in the frontline treatment of patients with inoperable or recurrent <em>EGFR</em>-positive non–small cell lung cancer.
Read More
Ramalingam Shares Notable Updates in NCCN Guidelines for EGFR+ NSCLC
November 27th 2017Suresh A. Ramalingam, MD, discusses some of the changes to the NCCN guidelines in NSCLC, specifically with <em>EGFR</em>-mutation–positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.
Read More